{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:51:54Z","timestamp":1791478314416,"version":"4.3.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent European and American dyslipidaemia guideline updates mark a relevant shift in preventive cardiology. The 2025 ESC\/EAS focused update and the 2026 ACC\/AHA guideline share the same biological premise: low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein B (ApoB)\u2013containing lipoproteins are causal drivers of atherosclerotic cardiovascular disease, and cardiovascular benefit depends on earlier, deeper, and sustained reduction of atherogenic burden. Their main differences lie in how prevention is organized in clinical practice. The European framework places greater emphasis on the explicit linkage between risk categories, predefined LDL-C goals, and treatment escalation. The American framework gives greater operational weight to lifetime risk, coronary artery calcium, non\u2013high-density lipoprotein cholesterol, ApoB, lipoprotein(a), treatment burden, and shared decision-making more directly into treatment selection. These differences influence patient classification, treatment intensity, and incorporation of non-statin therapies, particularly in borderline-risk primary prevention, subclinical atherosclerosis, and patients requiring combination therapy beyond statins. At the same time, both documents converge on key principles: reduced tolerance for prolonged exposure to atherogenic lipoproteins, broader use of combination lipid-lowering therapy, earlier intensification after acute coronary syndromes and in very high-risk settings, and selective use of biomarkers and imaging to refine prevention. Together, they offer complementary models of contemporary lipid management.<\/jats:p>","DOI":"10.1093\/eurjpc\/zwag413","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T11:33:08Z","timestamp":1786275188000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the 2025 ESC\/EAS and 2026 ACC\/AHA guidelines for dyslipidaemia management"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3974-3878","authenticated-orcid":false,"given":"Simone","family":"Finocchiaro","sequence":"first","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018Rodolico\u2014San Marco\u2019, University of Catania , Via Santa Sofia, 78, 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-9314","authenticated-orcid":false,"given":"Maria Sara","family":"Mauro","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018Rodolico\u2014San Marco\u2019, University of Catania , Via Santa Sofia, 78, 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5696-8707","authenticated-orcid":false,"given":"Costanza","family":"Bordonaro","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018Rodolico\u2014San Marco\u2019, University of Catania , Via Santa Sofia, 78, 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-1981","authenticated-orcid":false,"given":"Kamil","family":"Bujak","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018Rodolico\u2014San Marco\u2019, University of Catania , Via Santa Sofia, 78, 95123 Catania ,","place":["Italy"]},{"name":"Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia , Katowice ,","place":["Poland"]},{"name":"3rd Department of Cardiology, Silesian Center for Heart Diseases, Faculty of Medical Sciences in Zabrze, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5144-3722","authenticated-orcid":false,"given":"Chiara","family":"Cosentino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018Rodolico\u2014San Marco\u2019, University of Catania , Via Santa Sofia, 78, 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3536-8341","authenticated-orcid":false,"given":"Luigi","family":"Cutore","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018Rodolico\u2014San Marco\u2019, University of Catania , Via Santa Sofia, 78, 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3583-3331","authenticated-orcid":false,"given":"Giacinto","family":"Di Leo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018Rodolico\u2014San Marco\u2019, University of Catania , Via Santa Sofia, 78, 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3947-2205","authenticated-orcid":false,"given":"Francesco","family":"Nasisi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018Rodolico\u2014San Marco\u2019, University of Catania , Via Santa Sofia, 78, 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0585-4761","authenticated-orcid":false,"given":"Pietro","family":"Redigolo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018Rodolico\u2014San Marco\u2019, University of Catania , Via Santa Sofia, 78, 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018Rodolico\u2014San Marco\u2019, University of Catania , Via Santa Sofia, 78, 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026082607363270500_zwag413-B1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2026082607363270500_zwag413-B2","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"2026082607363270500_zwag413-B3","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026082607363270500_zwag413-B4","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2026082607363270500_zwag413-B5","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"SCORE2-OP working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2026082607363270500_zwag413-B6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"2026082607363270500_zwag413-B7","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2026082607363270500_zwag413-B8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"2026082607363270500_zwag413-B9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082607363270500_zwag413-B10","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"2026082607363270500_zwag413-B11","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","article-title":"Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)","volume":"39","author":"Budoff","year":"2018","journal-title":"Eur Heart J"},{"key":"2026082607363270500_zwag413-B12","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jcmg.2020.06.048","article-title":"Warranty period of a calcium score of zero: comprehensive analysis from MESA","volume":"14","author":"Dzaye","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026082607363270500_zwag413-B13","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jcmg.2023.03.008","article-title":"When does a calcium score equate to secondary prevention?: insights from the multinational CONFIRM registry","volume":"16","author":"Budoff","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026082607363270500_zwag413-B14","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.120.050545","article-title":"Very high coronary artery calcium (\u22651000) and association with cardiovascular disease events, non-cardiovascular disease outcomes, and mortality: results from MESA","volume":"143","author":"Peng","year":"2021","journal-title":"Circulation"},{"key":"2026082607363270500_zwag413-B15","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2023.06.040","article-title":"Association of coronary artery calcium detected by routine ungated CT imaging with cardiovascular outcomes","volume":"82","author":"Peng","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026082607363270500_zwag413-B16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/CIRCULATIONAHA.122.062746","article-title":"Incidental coronary artery calcium: opportunistic screening of previous nongated chest computed tomography scans to improve statin rates (NOTIFY-1 Project)","volume":"147","author":"Sandhu","year":"2023","journal-title":"Circulation"},{"key":"2026082607363270500_zwag413-B17","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","article-title":"Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium","volume":"394","author":"Brunner","year":"2019","journal-title":"Lancet"},{"key":"2026082607363270500_zwag413-B18","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"2026082607363270500_zwag413-B19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026082607363270500_zwag413-B20","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"2026082607363270500_zwag413-B21","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2026082607363270500_zwag413-B22","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026082607363270500_zwag413-B23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","article-title":"Independence of lipoprotein(a) and low-density lipoprotein cholesterol-mediated cardiovascular risk: a participant-level meta-analysis","volume":"151","author":"Bhatia","year":"2025","journal-title":"Circulation"},{"key":"2026082607363270500_zwag413-B24","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2026082607363270500_zwag413-B25","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026082607363270500_zwag413-B26","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082607363270500_zwag413-B27","doi-asserted-by":"crossref","first-page":"e2240513","DOI":"10.1001\/jamanetworkopen.2022.40513","article-title":"Quantification of utilization management barriers for patients initiating therapy to lower lipid levels","volume":"5","author":"O'Neil","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026082607363270500_zwag413-B28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2026082607363270500_zwag413-B29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026082607363270500_zwag413-B30","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082607363270500_zwag413-B31","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/eurjpc\/zwaf048","article-title":"Reappraisal of statin primary prevention trials: implications for identification of the statin-eligible primary prevention patient","volume":"32","author":"Mancini","year":"2025","journal-title":"Eur J Prev Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag413\/70612903\/zwag413.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag413\/70612903\/zwag413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:36:41Z","timestamp":1787744201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag413\/8759025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag413","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"zwag413"}}